Tivic Health enters $4.1M GMP manufacturing agreement with Scorpius for Entolimod ARS

Valion Bio, Inc.

Scorpius BioManufacturing to perform GMP validation for Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS).
Total estimated investment ~$4.1M comprising ~$2.4M service fees and pass-through costs for consumables, external services.
Scorpius to perform cell line verification, GMP scale-up, fill/finish, analytical development, process optimization.
Purpose is to prepare complete CMC package for FDA BLA submission for Entolimod.
Manufacturing at Scorpius' San Antonio, TX facility; aims for leaner supply chain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.